U.S. markets open in 8 hours 4 minutes

Apellis Pharmaceuticals, Inc. (APLS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
53.87+3.57 (+7.10%)
At close: 04:00PM EST
53.75 -0.12 (-0.22%)
After hours: 07:38PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close50.30
Bid0.00 x 800
Ask0.00 x 2900
Day's Range50.52 - 54.96
52 Week Range19.83 - 94.75
Avg. Volume2,291,862
Market Cap6.384B
Beta (5Y Monthly)0.97
PE Ratio (TTM)N/A
EPS (TTM)-5.23
Earnings DateFeb 19, 2024 - Feb 23, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est71.19
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for APLS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Apellis Pharmaceuticals, Inc.
    Analyst Report: argenx SEArgenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more